Unknown

Dataset Information

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.


ABSTRACT: The androgen receptor (AR) is widely expressed in breast cancer, and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown success in preclinical models and clinical trials of prostate cancer and are currently being evaluated in breast cancer. Reciprocal regulation between AR and the HER2/PI3K/mTOR pathway may contribute to resistance to HER2- and mTOR-targeted therapies; thus, dual inhibition of these pathways may synergistically inhibit breast cancer growth. HER2+ and triple-negative breast cancer cell lines were treated with AR antagonist plus anti-HER2 mAb trastuzumab or mTOR inhibitor everolimus. Apoptosis, cell proliferation, and drug synergy were measured in vitro Pathway component genes

SUBMITTER: Gordon MA 

PROVIDER: S-EPMC5517319 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature